Condition (MeSH)
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
ClinicalTrials.gov lists 38 trials for Precursor B-Cell Lymphoblastic Leukemia-Lymphoma or a narrower condition beneath it. Children's Oncology Group has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
38 of the 38 trials are tagged with Precursor B-Cell Lymphoblastic Leukemia-Lymphoma itself; the rest are tagged with a narrower condition beneath it.
When did Precursor B-Cell Lymphoblastic Leukemia-Lymphoma trials start? (15)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 4 |
| 2024 | 5 |
| 2023 | 3 |
| 2021 | 1 |
| 2019 | 5 |
| 2018 | 3 |
| 2017 | 3 |
| 2016 | 1 |
| 2013 | 3 |
Showing 10 of 15 earlier years.
No forecast is made for this condition: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 8 trials still running at the 2026-10-09 snapshot; registered median of 39 months across 14 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Precursor B-Cell Lymphoblastic Leukemia-Lymphoma trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 1/2 | 10 |
| Phase 2 | 12 |
| Phase 2/3 | 1 |
| Phase 3 | 4 |
| Phase 4 | 1 |
| Not applicable | 2 |
| Observational | 3 |
How many Precursor B-Cell Lymphoblastic Leukemia-Lymphoma trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 12 |
| Active, not recruiting | 6 |
| Completed | 9 |
| Terminated | 3 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Precursor B-Cell Lymphoblastic Leukemia-Lymphoma trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Children's Oncology Group | 3 |
| Seagen Inc. | 2 |
| Ankara Children's Health and Diseases Hematology and Oncology Training and Research Hospital | 1 |
| ECOG-ACRIN Cancer Research Group | 1 |
| Fate Therapeutics | 1 |
Which drugs are being tested for Precursor B-Cell Lymphoblastic Leukemia-Lymphoma? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cytoxan | 15 |
| Prednisone | 7 |
| MERCAPTOPURINE | 5 |
| Calcium Leucovorin | 4 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Dexamethasone/Dexamethasone acetate | 13 |
| Cytarabine IT | 11 |
| Vincristina | 11 |
| HD- Methotrexate (MTX) | 9 |
| Doxorubicine | 7 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Precursor B-Cell Lymphoblastic Leukemia-Lymphoma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Sepsis | 51 | 3 |
| Febrile neutropenia | 32 | 3 |
| Respiratory failure | 20 | 3 |
| Venoocclusive liver disease | 18 | 1 |
| Death NOS | 17 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Precursor B-Cell Lymphoblastic Leukemia-Lymphoma? (196)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children. | The New England journal of medicine | 2025 | Yes |
| Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies. | Blood | 2025 | Yes |
| Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALL. | Blood | 2025 | Yes |
| CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy. | Journal for immunotherapy of cancer | 2025 | Yes |
| Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia. | Blood advances | 2025 | Yes |
Showing 5 of 196 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.